» Articles » PMID: 35906002

Cross-species Transcriptome Analysis for Early Detection and Specific Therapeutic Targeting of Human Lupus Nephritis

Abstract

Objectives: Patients with lupus nephritis (LN) are in urgent need for early diagnosis and therapeutic interventions targeting aberrant molecular pathways enriched in affected kidneys.

Methods: We used mRNA-sequencing in effector (spleen) and target (kidneys, brain) tissues from lupus and control mice at sequential time points, and in the blood from 367 individuals (261 systemic lupus erythematosus (SLE) patients and 106 healthy individuals). Comparative cross-tissue and cross-species analyses were performed. The human dataset was split into training and validation sets and machine learning was applied to build LN predictive models.

Results: In murine SLE, we defined a kidney-specific molecular signature, as well as a molecular signature that underlies transition from preclinical to overt disease and encompasses pathways linked to metabolism, innate immune system and neutrophil degranulation. The murine kidney transcriptome partially mirrors the blood transcriptome of patients with LN with 11 key transcription factors regulating the cross-species active LN molecular signature. Integrated protein-to-protein interaction and drug prediction analyses identified the kinases TRRAP, AKT2, CDK16 and SCYL1 as putative targets of these factors and capable of reversing the LN signature. Using murine kidney-specific genes as disease predictors and machine-learning training of the human RNA-sequencing dataset, we developed and validated a peripheral blood-based algorithm that discriminates LN patients from normal individuals (based on 18 genes) and non-LN SLE patients (based on 20 genes) with excellent sensitivity and specificity (area under the curve range from 0.80 to 0.99).

Conclusions: Machine-learning analysis of a large whole blood RNA-sequencing dataset of SLE patients using human orthologs of mouse kidney-specific genes can be used for early, non-invasive diagnosis and therapeutic targeting of LN. The kidney-specific gene predictors may facilitate prevention and early intervention trials.

Citing Articles

Comparative Transcriptome Analysis of Bovine, Porcine, and Sheep Muscle Using Interpretable Machine Learning Models.

Guo Y, Li S, Na R, Guo L, Huo C, Zhu L Animals (Basel). 2024; 14(20).

PMID: 39457877 PMC: 11506101. DOI: 10.3390/ani14202947.


Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis.

Parodis I, Lindblom J, Toro-Dominguez D, Beretta L, Borghi M, Castillo J Kidney Int Rep. 2024; 9(6):1817-1835.

PMID: 38899167 PMC: 11184261. DOI: 10.1016/j.ekir.2024.03.014.


Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events.

Nikolopoulos D, Loukogiannaki C, Sentis G, Garantziotis P, Manolakou T, Kapsala N Ann Rheum Dis. 2024; 83(9):1132-1143.

PMID: 38609158 PMC: 11420729. DOI: 10.1136/ard-2024-225664.


Immune and molecular landscape behind non-response to Mycophenolate Mofetil and Azathioprine in lupus nephritis therapy.

Lopez-Dominguez R, Villatoro-Garcia J, Maranon C, Goldman D, Petri M, Carmona-Saez P Res Sq. 2024; .

PMID: 38260685 PMC: 10802741. DOI: 10.21203/rs.3.rs-3783877/v1.


A network-based approach reveals long non-coding RNAs associated with disease activity in lupus nephritis: key pathways for flare and potential biomarkers to be used as liquid biopsies.

Sentis G, Loukogiannaki C, Malissovas N, Nikolopoulos D, Manolakou T, Flouda S Front Immunol. 2023; 14:1203848.

PMID: 37475860 PMC: 10355154. DOI: 10.3389/fimmu.2023.1203848.


References
1.
Berthier C, Bethunaickan R, Gonzalez-Rivera T, Nair V, Ramanujam M, Zhang W . Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis. J Immunol. 2012; 189(2):988-1001. PMC: 3392438. DOI: 10.4049/jimmunol.1103031. View

2.
Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho A, Andrassy K . Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis. 2003; 62(5):435-9. PMC: 1754523. DOI: 10.1136/ard.62.5.435. View

3.
Fanouriakis A, Kostopoulou M, Cheema K, Anders H, Aringer M, Bajema I . 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924. View

4.
Furie R, Rovin B, Houssiau F, Malvar A, Teng Y, Contreras G . Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020; 383(12):1117-1128. DOI: 10.1056/NEJMoa2001180. View

5.
Reimand J, Kull M, Peterson H, Hansen J, Vilo J . g:Profiler--a web-based toolset for functional profiling of gene lists from large-scale experiments. Nucleic Acids Res. 2007; 35(Web Server issue):W193-200. PMC: 1933153. DOI: 10.1093/nar/gkm226. View